Reported 2 days ago
B. Riley has decreased its price target for Viking Therapeutics (VKTX) from $109 to $96, while maintaining a Buy rating on the stock. The firm remains optimistic, noting encouraging results from the oral VK2735 related to weight loss, perceived as unique in the market.
Source: YAHOO